Histone Deacetylase Inhibitors Market Trends 2025–2029: Regional Outlook and Sizing Analysis
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Big Is The Histone Deacetylase Inhibitors Market Today And What Is Its Future Size?
Over the recent years, the histone deacetylase inhibitors market has made solid growth. The market is expected to grow from $1.2 billion in 2024 to $1.29 billion in 2025, projecting a compound annual growth rate (CAGR) of 7.2%. Factors such as regulatory backing, accelerated approvals, a growing number of cancer cases, increased investment in cancer research, the widening of therapeutic applications, and heightened spending on healthcare infrastructure have contributed to the growth during this historical period.
The market size for histone deacetylase inhibitors is predicted to experience considerable growth in the coming years, escalating to “$1.71 billion in 2029” with a compound annual growth rate (CAGR) of 7.2%. This growth during the forecast period can be accounted for by increasing investments in biotechnology, the rising elderly population, positive regulatory endorsements, expedited drug approval processes, enhanced drug delivery systems, and the broadening of therapeutic applications. Key trends during this forecast period encompass the incorporation of wearable devices for patient health monitoring, breakthroughs in nanotechnology and drug delivery procedures, progress in identifying and validating biomarkers, the application of artificial intelligence (AI) and machine learning, and the development of next-generation sequencing.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
What Market Forces Are Contributing To The Growth Of The Histone Deacetylase Inhibitors Market?
The histone deacetylase inhibitors market is set to surge due to the growing number of cancer cases. The surge in cancer incidences primarily links to factors such as aging populations, increased risk exposure through tobacco use, diet, and environmental pollutants, as well as advanced diagnostic techniques that allow for early and frequent detection. Histone deacetylase inhibitors combat cancer by adjusting chromatin structure, which then triggers the activation of tumor suppressor genes and inhibits oncogenes, leading to cancer cell cycle arrest and apoptosis. For instance, the World Health Organization, a U.S.-based intergovernmental organization, predicted about 35 million new cancer cases in 2050 in February 2024, a 77% surge from the estimated 20 million cases in 2022. As such, the rising occurrence of cancer is fuelling the expansion of the histone deacetylase inhibitors market.
Which Segmentation Factors Are Critical In The Histone Deacetylase Inhibitors Market Analysis?
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)
What Are The Dominant Trends Currently Seen In The Histone Deacetylase Inhibitors Market?
Leading firms in the histone deacetylase inhibitors industry are concentrating on creating ground-breaking product formulas, such as oral histone deacetylase (HDAC) inhibitors, to broaden treatment methods and better patient comfort and adherence. An oral HDAC inhibitor is a type of medication ingested orally to target HDAC enzymes that regulate genes and could potentially address a range of diseases like cancer and inflammatory conditions. For example, Italfarmaco S.p.A., a pharmaceutical firm from Italy, secured approval from the Food and Drug Administration in March 2024 for Duvyzat (givinostat), an oral HDAC inhibitor, to administer for Duchenne muscular dystrophy (DMD) in patients aged 6 years and over. Duvyzat, as an HDAC inhibitor, suppresses the successive events resulting in muscle damage, possibly delaying the progression of muscle degradation related to DMD. It counteracts HDAC overactivity, minimizing inflammation and fibrosis, while encouraging the regeneration of muscle fibers. The endorsement was based on the crucial phase 3 EPIDYS trial that achieved its primary aim, proving that patients taking Duvyzat exhibited a significant reduction in the time to finish the four-stair climb assessment compared to a placebo.
Which Companies Hold A Competitive Edge In The 419 Market?
Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC
Access The Complete Report Here:
Which Region Is Leading Innovation In The Histone Deacetylase Inhibitors Market?
North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=17170&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
